Moreover, combined treatment with EOAI34 (a USP5 inhibitor) and trametinib (a MEK inhibitor) in CT26 tumor-bearing mice slowed tumor growth and increased CD8+ T-cell infiltration [20] (Table 1). Here, MAP2K7 is linked to neoplasm.